Fosamax vs Prolia (Denosumab): Side-Effect Profile Head-to-Head

What Is Each Drug and How Do They Work?

Alendronate is a nitrogen-containing bisphosphonate that binds hydroxyapatite in bone and inhibits osteoclast-mediated resorption by blocking the mevalonate pathway enzyme farnesyl pyrophosphate synthase. Denosumab is a fully human monoclonal antibody that neutralizes RANK ligand, preventing osteoclast formation entirely. These are fundamentally different mechanisms, which explains why their side-effect profiles diverge so sharply.

Alendronate: Oral Bisphosphonate Basics

Alendronate was FDA-approved for postmenopausal osteoporosis in 1995. The standard regimen is 70 mg orally once weekly, taken with a full glass of plain water at least 30 minutes before any food, beverage, or other medication. The FDA label specifies this fasting requirement to achieve the drug's already-low oral bioavailability of roughly 0.6%. Patients must remain upright for 30 minutes after ingestion to reduce esophageal contact time.

Denosumab: RANK-L Inhibitor Basics

Denosumab 60 mg is injected subcutaneously every 6 months by a healthcare provider. The FDA approved Prolia in June 2010 for postmenopausal women at high fracture risk and for men with osteoporosis. Because it is a biologic antibody, it is not absorbed through the GI tract and therefore sidesteps the upper GI side effects that limit alendronate in many patients.

Fracture Efficacy: What the Landmark Trials Show

Both drugs reduce vertebral fractures significantly, but the direct numerical comparison favors denosumab in published trial data. No head-to-head randomized controlled trial has compared fracture outcomes between these two drugs directly, so all efficacy comparisons draw on separate trial populations.

FIT Trial (Alendronate)

The Fracture Intervention Trial (FIT), published in JAMA 1998, enrolled 2,027 postmenopausal women aged 55 to 81 with low femoral neck BMD. Over 3 years, alendronate produced a 47% relative risk reduction in morphometric vertebral fractures compared with placebo (8.0% vs. 15.0%; P<0.001). Hip fracture risk fell by 51% in women with existing vertebral fractures at baseline.

FREEDOM Trial (Denosumab)

The FREEDOM trial, published in the New England Journal of Medicine 2009, enrolled 7,868 postmenopausal women aged 60 to 90. Denosumab reduced new vertebral fractures by 68% over 3 years (2.3% vs. 7.2%; P<0.001) and hip fractures by 40% (0.7% vs. 1.2%; P=0.04). The larger relative risk reduction compared to FIT reflects both the higher baseline fracture rate in FREEDOM's older population and denosumab's more complete osteoclast suppression.

Cross-Trial Caution

Direct numerical comparison across FIT and FREEDOM is confounded by different mean ages, T-score entry criteria, and calendar-era differences in background calcium supplementation. A network meta-analysis published in the Journal of Bone and Mineral Research found denosumab numerically superior to alendronate for vertebral and hip fracture reduction, but confidence intervals overlapped for hip fracture. The American Association of Clinical Endocrinology (AACE) 2020 guidelines designate both drugs as first-line agents for high-risk postmenopausal osteoporosis. Clinicians should select based on individual risk factors rather than fracture-reduction numbers alone.

Gastrointestinal Side Effects: Alendronate's Primary Liability

Gastrointestinal tolerability is one of the clearest practical differentiators between these two drugs. Alendronate's oral route exposes the esophageal and gastric mucosa to a highly acidic, irritating compound.

Esophageal and Gastric Irritation

Upper GI adverse events occur in 10 to 30% of alendronate users in observational studies, with esophageal ulceration and esophagitis among the most serious. The FDA added a label warning for esophageal adverse reactions after post-marketing reports of severe esophagitis, esophageal ulcers, and esophageal erosions, some requiring hospitalization. Patients with Barrett's esophagus, active esophageal disease, or achalasia are generally not candidates for alendronate.

Denosumab and GI Tolerability

Denosumab produces no direct GI mucosal effects. In FREEDOM, the rate of gastrointestinal adverse events was similar between denosumab and placebo groups, with no increase in esophageal or gastric events. For patients who have failed or cannot tolerate oral bisphosphonates due to upper GI disease, denosumab is a preferred alternative per the Endocrine Society clinical practice guidelines. The Endocrine Society states that denosumab "is an appropriate choice for patients who cannot tolerate oral bisphosphonates."

Hypocalcemia: A Denosumab-Specific Risk

Denosumab suppresses osteoclast activity so completely that calcium flux from bone into circulation drops sharply, particularly in patients with pre-existing vitamin D deficiency or impaired renal function.

Magnitude and Timing

The FDA label for Prolia carries a warning that hypocalcemia has been reported, is more common in patients with renal impairment, and can be severe and symptomatic. A 2012 case series in the Journal of Clinical Endocrinology and Metabolism documented symptomatic hypocalcemia in up to 5.9% of patients with advanced chronic kidney disease receiving denosumab for cancer-related bone disease, though rates are lower in the osteoporosis population. Correcting 25-hydroxyvitamin D to above 30 ng/mL and ensuring adequate calcium intake before the first denosumab dose is recommended by both the AACE and the National Osteoporosis Foundation. Alendronate does not cause clinically significant hypocalcemia when vitamin D and calcium status are normal.

Monitoring Protocol

Clinicians should check serum calcium and 25-hydroxyvitamin D before each denosumab injection. The NOF recommends 1,200 mg elemental calcium daily and 800 to 1,000 IU vitamin D3 daily for postmenopausal women on bone-active therapies. No comparable pre-dose monitoring is required for alendronate in patients with normal renal function.

Serious Infections: A Denosumab-Specific Signal

RANK-L is expressed on immune cells beyond osteoclasts, including dendritic cells and T lymphocytes. Complete RANK-L blockade may modestly impair host defenses.

Cellulitis and Serious Infections in FREEDOM

In FREEDOM, serious infections (requiring hospitalization) occurred in 4.1% of denosumab patients vs. 3.4% of placebo patients, with a statistically significant increase in skin infections including cellulitis (0.3% vs. 0.1%; P=0.002). The absolute risk difference is small, but clinicians should counsel patients to seek prompt evaluation for skin redness, warmth, or fever. Alendronate carries no comparable infection risk signal.

Endocarditis Signal

A 2019 observational study in the BMJ found a possible association between denosumab and endocarditis risk (adjusted HR 1.76, 95% CI 1.14 to 2.72), though causality was not established. This signal has not been replicated in randomized data and the FDA has not added an endocarditis warning to the Prolia label. Clinicians treating patients with valvular heart disease or prosthetic valves may want to document this uncertainty in their shared decision-making discussion.

Osteonecrosis of the Jaw (ONJ): Shared but Rare Risk

ONJ is a rare but serious adverse event shared by both drugs. The jaw experiences high bone turnover from mastication-related mechanical loading, making it more susceptible to the bone remodeling suppression both agents cause.

Incidence Rates

In patients receiving alendronate for osteoporosis (as opposed to higher-dose IV bisphosphonates for cancer), ONJ incidence is estimated at 1 in 10,000 to 1 in 100,000 patient-years by the American Society for Bone and Mineral Research task force report. For denosumab at the osteoporosis dose of 60 mg every 6 months, the rate is similarly rare. A 2015 meta-analysis in the Journal of Bone and Mineral Research found pooled ONJ incidence of 0.04% across denosumab osteoporosis trials. Rates are dramatically higher (up to 2%) with the cancer doses of both drug classes.

Risk Factors and Prevention

Shared risk factors include poor oral hygiene, dentoalveolar surgery (especially extractions), corticosteroid use, and diabetes. The American Dental Association recommends patients complete necessary invasive dental work before starting either a bisphosphonate or denosumab and maintain vigilant oral hygiene throughout therapy. Neither drug mandates a mandatory pre-treatment dental examination per FDA labeling, but most guidelines strongly advise it.

Atypical Femur Fractures (AFF): Shared but Dose-Duration-Dependent Risk

AFF is a stress fracture of the subtrochanteric or femoral shaft that occurs with little or no trauma. Both antiresorptive agents suppress bone turnover to a degree that may impair microdamage repair.

Alendronate Duration and AFF

An FDA safety communication in 2010 confirmed that AFF risk increases with longer bisphosphonate duration, particularly beyond 5 years of continuous use. A Swedish cohort study (N=12,777) reported that the absolute 2-year risk of AFF was 11 per 10,000 in women on bisphosphonates for 3 years and rose to 78 per 10,000 in those treated for 8 to 9 years. This duration-dependent risk is the primary reason the 2022 AACE/ACE guidelines recommend a bisphosphonate "drug holiday" after 5 years of oral therapy in moderate-risk patients.

Denosumab and AFF

Post-marketing reports have confirmed AFF in denosumab-treated patients, and the FDA updated the Prolia label in 2020 to include AFF as a known risk. The long-term FREEDOM Extension study (10 years of denosumab, N=4,550 cumulative) reported 12 AFF cases, yielding an incidence rate of roughly 6 per 10,000 patient-years, a rate broadly comparable to long-term bisphosphonate use. The FREEDOM Extension results are published in the Journal of Bone and Mineral Research.

The Rebound Effect: Denosumab's Unique Discontinuation Risk

This is the single most clinically consequential difference between the two drugs. It is not a side effect of taking denosumab; it is a side effect of stopping it.

Rapid Bone Loss and Multiple Vertebral Fractures

When denosumab is discontinued, RANK-L activity rebounds above pre-treatment levels because RANK-L gene transcription was suppressed during therapy and is now upregulated. A 2017 analysis in Osteoporosis International demonstrated that patients who stopped denosumab lost all accrued BMD gains within 12 months and returned to pre-treatment fracture risk levels. More alarming, multiple spontaneous vertebral fractures occurring in clusters have been reported. A 2019 systematic review in the Journal of Bone and Mineral Research identified 56 published cases of rebound-associated vertebral fracture after denosumab discontinuation, with 60% of cases involving multiple simultaneous fractures.

Bridging Strategy Is Mandatory

Current AACE/ACE 2022 guidelines recommend transitioning to an oral bisphosphonate (alendronate 70 mg weekly for at least 12 months) immediately after the last denosumab dose if discontinuation is necessary. Alendronate has no comparable rebound phenomenon because it remains incorporated in bone matrix for years after discontinuation, providing a residual antiresorptive effect. The FDA has issued a communication highlighting the risk of multiple vertebral fractures after denosumab discontinuation and urging prescribers to discuss this with patients before initiating therapy.

Renal Function: A Practical Prescribing Differentiator

Renal impairment affects both drug selection and monitoring requirements in meaningful ways.

Alendronate and CrCl Thresholds

Alendronate is contraindicated in patients with creatinine clearance <35 mL/min per its FDA label, because renal excretion is the sole elimination route and accumulation risk is uncertain. Patients with CKD stage 3b (CrCl 30 to 44 mL/min) fall in a gray zone, and many clinicians avoid it beyond stage 3a.

Denosumab in CKD

Denosumab requires no dose adjustment for renal impairment because it is eliminated via the reticuloendothelial system, not the kidneys. However, the FDA label warns that patients with CrCl <30 mL/min are at greater risk of severe hypocalcemia, requiring more frequent calcium and vitamin D monitoring. A 2018 cohort study in JAMA Internal Medicine (N=11,802 CKD patients) confirmed that denosumab was associated with reduced fracture risk in CKD stages 3 and 4, while bisphosphonate use was uncommon in that population. That study is indexed at PubMed.

Adherence and Convenience: Real-World Persistence

Efficacy data from trials assumes near-perfect adherence. Real-world persistence differs substantially between the two agents.

Oral Bisphosphonate Adherence Challenges

The weekly fasting ritual and upright posturing requirements for alendronate drive non-adherence. A systematic review in Osteoporosis International reported that fewer than 50% of patients remained adherent to oral bisphosphonates at 12 months in real-world settings. GI side effects are the most common reported reason for discontinuation.

Denosumab Persistence Rates

Twice-yearly subcutaneous injection reduces dosing frequency dramatically. In the DAPS trial (N=250), denosumab showed superior medication persistence at 24 months compared with alendronate (87.8% vs. 72.7%, P<0.001). The trade-off is clinic visit burden and the critical importance of not missing or delaying an injection beyond the 7-month mark, since delayed dosing accelerates rebound bone loss. The AACE 2022 guidelines note that a missed denosumab dose by more than one month beyond the scheduled 6-month interval should prompt urgent follow-up to prevent rapid bone loss.

Cost and Insurance Considerations

Alendronate is available as a low-cost generic. The average retail price for a 4-week supply of generic alendronate 70 mg is under $20 USD with GoodRx pricing. Prolia (denosumab) remains a brand-only biologic with a list price of approximately $1,300 per injection, or about $2,600 annually. Medicare Part B covers Prolia injections administered in an office setting, but prior authorization is commonly required, particularly when bisphosphonate naivety cannot be documented. For patients without comprehensive drug coverage, alendronate's cost advantage is substantial. Clinicians at HealthRX typically verify formulary coverage and patient-assistance program eligibility before prescribing denosumab as a first-line agent.

Who Should Get Alendronate vs. Denosumab? A Clinical Decision Framework

The choice between alendronate and denosumab is not binary. Several patient characteristics tip the balance clearly in one direction.

Situations Favoring Alendronate

• Normal renal function (CrCl >35 mL/min) and no upper GI disease
• Cost sensitivity or limited insurance coverage
• Patients who prefer oral medication and can reliably follow the fasting protocol
• Patients with no current plans for long-term sequential therapy management (lower planning burden on discontinuation)
• Men with osteoporosis not requiring the fastest possible BMD gain

Situations Favoring Denosumab

• Upper GI intolerance or contraindication to oral bisphosphonates (esophageal disease, inability to sit upright for 30 minutes)
• CKD stage 3b or 4, where alendronate is contraindicated or inadvisable
• Patients who are unlikely to adhere to weekly oral dosing but can attend twice-yearly injections
• Very high fracture risk requiring the largest available BMD gains quickly
• Patients already managed in a specialty clinic where injection administration and calcium monitoring are routine

Patients who choose denosumab must commit to a clear exit strategy from day one. The AACE 2022 guidelines are explicit: "Denosumab should not be discontinued without a plan for sequential therapy, as abrupt discontinuation is associated with rapid bone loss and increased fracture risk."

Can You Switch from Fosamax to Prolia (Denosumab)?

Yes. Switching from alendronate to denosumab is straightforward and commonly done when fracture risk remains high after several years on oral bisphosphonate therapy or when GI tolerability worsens. A 2012 study published in Osteoporosis International (N=504) showed that women who switched from alendronate to denosumab gained significantly more hip and lumbar spine BMD over 12 months compared with those who continued alendronate. The residual alendronate in bone does not appear to blunt denosumab's anabolic-adjacent remodeling suppression.

Switching from denosumab back to alendronate requires immediate initiation (within 7 months of the last denosumab dose) and sustained oral bisphosphonate therapy for at least 12 to 24 months to prevent rebound. A 2021 study in the Journal of Bone and Mineral Research confirmed that 12 months of post-denosumab alendronate attenuated but did not fully prevent BMD loss in all patients, underscoring why high-risk patients may need 24 months of bridging.